血管紧张素转换酶抑制剂(ACEI)革新了充血性心力衰竭、高血压和糖尿病肾病的治疗。在心肌梗塞后,给予 ACEI 治疗可以降低致死性左心衰竭的发生率,以及提高病人的生存率。然而,尽管ACEI 好象是治疗血管疾病的良药,但是,对于无症状性动脉硬化性肾动脉狭窄病人应用 ACEI 药物则可发生危险,且其危害将日益加重。传统观点认为:如果病人在接受 ACEI 治疗若 Angiotensin-converting enzyme inhibitors (ACEIs) revolutionize the treatment of congestive heart failure, hypertension and diabetic nephropathy. After myocardial infarction, given ACEI treatment can reduce the incidence of fatal left heart failure, and improve patient survival. However, although ACEI seems to be a good medicine for the treatment of vascular diseases, the use of ACEI drugs in asymptomatic patients with atherosclerotic renal artery stenosis can be dangerous and its harm will be aggravated. The traditional view that: If the patient undergoing ACEI treatment if